PL2004181T3 - Modulator receptorów androgenowych do leczenia raka prostaty i chorób powiązanych z receptorami androgenowymi - Google Patents

Modulator receptorów androgenowych do leczenia raka prostaty i chorób powiązanych z receptorami androgenowymi

Info

Publication number: PL2004181T3
Authority: PL; Poland
Prior art keywords: androgen receptor; treatment; prostate cancer; associated diseases; receptor modulator
Prior art date: 2006-03-27

Application number

PL07754060T

Other languages

English (en)

Other versions

PL2004181T6 (pl

Inventor

Michael E Jung

Charles L Sawyers

Samedy Ouk

Chris Tran

John Wongvipat

Original Assignee

Univ California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-03-27

Filing date

2007-03-27

Publication date

2016-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38656005&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2004181(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-03-27 Application filed by Univ California filed Critical Univ California

2016-06-30 Publication of PL2004181T3 publication Critical patent/PL2004181T3/pl

2023-09-04 Publication of PL2004181T6 publication Critical patent/PL2004181T6/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Pregnancy & Childbirth (AREA)
Urology & Nephrology (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)

PL07754060.7T 2006-03-27 2007-03-27 Modulator receptorów androgenowych do leczenia raka prostaty i chorób powiązanych z receptorami androgenowymi PL2004181T6 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US78597806P	2006-03-27	2006-03-27
US83379006P	2006-07-28	2006-07-28
EP07754060.7A EP2004181B3 (en)	2006-03-27	2007-03-27	Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
PCT/US2007/007485 WO2007126765A2 (en)	2006-03-27	2007-03-27	Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases

Publications (2)

Publication Number	Publication Date
PL2004181T3 true PL2004181T3 (pl)	2016-06-30
PL2004181T6 PL2004181T6 (pl)	2023-09-04

Family

ID=38656005

Family Applications (6)

Application Number	Title	Priority Date	Filing Date
PL18181743T PL3412290T3 (pl)	2006-03-27	2007-03-27	Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym
PL16173574T PL3100727T3 (pl)	2006-03-27	2007-03-27	Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym
PL13178051T PL2656842T3 (pl)	2006-03-27	2007-03-27	Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym
PL07754060.7T PL2004181T6 (pl)	2006-03-27	2007-03-27	Modulator receptorów androgenowych do leczenia raka prostaty i chorób powiązanych z receptorami androgenowymi
PL11163948T PL2368550T3 (pl)	2006-03-27	2007-03-27	Modulator receptorów androgenowych do leczenia raka gruczołu krokowego i chorób związanych z receptorami androgenów
PL13178047T PL2656841T3 (pl)	2006-03-27	2007-03-27	Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
PL18181743T PL3412290T3 (pl)	2006-03-27	2007-03-27	Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym
PL16173574T PL3100727T3 (pl)	2006-03-27	2007-03-27	Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym
PL13178051T PL2656842T3 (pl)	2006-03-27	2007-03-27	Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PL11163948T PL2368550T3 (pl)	2006-03-27	2007-03-27	Modulator receptorów androgenowych do leczenia raka gruczołu krokowego i chorób związanych z receptorami androgenów
PL13178047T PL2656841T3 (pl)	2006-03-27	2007-03-27	Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym

Country Status (19)

Country	Link
US (7)	US8445507B2 (pl)
EP (8)	EP2656842B1 (pl)
JP (10)	JP5133975B2 (pl)
CN (1)	CN101454002B (pl)
AU (1)	AU2007243651C1 (pl)
BR (1)	BRPI0709771B1 (pl)
CY (7)	CY1114623T1 (pl)
DK (6)	DK2656842T3 (pl)
ES (6)	ES2863798T3 (pl)
FI (1)	FI2004181T6 (pl)
HU (6)	HUE042037T2 (pl)
LT (5)	LT2656841T (pl)
LU (1)	LUC00123I2 (pl)
NL (1)	NL300993I2 (pl)
NZ (1)	NZ572335A (pl)
PL (6)	PL3412290T3 (pl)
PT (5)	PT2368550E (pl)
SI (6)	SI3412290T1 (pl)
WO (1)	WO2007126765A2 (pl)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE602004031881D1 (de)	2003-12-19	2011-04-28	Univ California	Verfahren und materialien zur beurteilung von prostatakrebstherapien
WO2005099693A2 (en)	2004-02-24	2005-10-27	The Regents Of The University Of California	Methods and materials for assessing prostate cancer therapies and compounds
US7709517B2 (en) *	2005-05-13	2010-05-04	The Regents Of The University Of California	Diarylhydantoin compounds
PL3412290T3 (pl)	2006-03-27	2021-09-06	The Regents Of The University Of California	Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym
CA2648139A1 (en)	2006-03-29	2007-11-08	The Regents Of The University Of California	Diaryl thiohydantoin compounds and their use in the treatment of hyperproliferative disorders
WO2008119015A2 (en)	2007-03-27	2008-10-02	Sloan-Kettering Institute For Cancer Research	Synthesis of thiohydantoins
US8680291B2 (en)	2007-10-26	2014-03-25	The Regents Of The University Of California	Diarylhydantoin compounds
FR2944524B1 (fr) *	2009-04-17	2012-11-30	Ipsen Pharma Sas	Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
EP2475647B1 (en) *	2009-09-10	2015-11-04	Suzhou Kintor Pharmaceuticals, Inc.	Androgen receptor antagonists and uses thereof
BR112012015868A2 (pt)	2009-12-11	2017-06-20	Autifony Therapeutics Ltd	derivados de imidazolidinadiona
JP5702595B2 (ja) *	2009-12-25	2015-04-15	石原産業株式会社	２−クロロ−３−トリフルオロメチルピリジンの製造方法
AU2014271290C1 (en) *	2010-02-16	2016-10-27	Aragon Pharmaceuticals, Inc.	Androgen receptor modulators and uses thereof
EA028869B1 (ru) *	2010-02-16	2018-01-31	Арагон Фармасьютикалс, Инк.	Модуляторы рецептора андрогенов и их применение
AU2016208310B2 (en) *	2010-02-16	2017-10-05	Aragon Pharmaceuticals, Inc.	Androgen receptor modulators and uses thereof
EP2538785B1 (en) *	2010-02-24	2018-03-21	Medivation Prostate Therapeutics LLC	Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds
WO2012076877A1 (en)	2010-12-06	2012-06-14	Autifony Therapeutics Limited	Hydantoin derivatives useful as kv3 inhibitors
EP2718285B1 (en)	2011-06-07	2016-03-16	Autifony Therapeutics Limited	Hydantoin derivatives as kv3 inhibitors
CN103997894B (zh)	2011-07-29	2016-08-24	麦迪韦逊前列腺治疗股份有限公司	乳癌的治疗
US9708276B2 (en)	2011-10-12	2017-07-18	University of Pittsburgh—of the Commonwealth System of Higher Education	Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
WO2013056547A1 (zh) *	2011-10-22	2013-04-25	Chen Degui	一组乙内酰脲衍生物的合成及其应用
CN103159680A (zh) *	2011-12-14	2013-06-19	爱美尼迪药物有限公司	咪唑二酮类化合物及其用途
UY34646A (es)	2012-03-02	2013-10-31	Novartis Ag	Compuestos de espirohidantoína y su uso como moduladores selectivos del receptor de andrógenos
WO2013152342A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Anti-cancer mtor inhibitor and anti-androgen combination
BR112014028718A2 (pt)	2012-05-22	2017-06-27	Autifony Therapeutics Ltd	derivados de hidantoína como inibidores de kv3
CN104334547B (zh)	2012-05-22	2017-06-06	奥蒂福尼疗法有限公司	作为kv3抑制剂的三唑类
ES2809738T3 (es)	2012-06-07	2021-03-05	Aragon Pharmaceuticals Inc	Formas cristalinas de un modulador de receptor de andrógenos
WO2014043208A1 (en)	2012-09-11	2014-03-20	Medivation Prostate Therapeutics, Inc.	Formulations of enzalutamide
PT3305285T (pt)	2012-09-26	2020-11-24	Aragon Pharmaceuticals Inc	Antiandrogénios para o tratamento de cancro da próstata resistente à castração não metastático
US9175291B2 (en)	2012-10-11	2015-11-03	Isis Pharmaceuticals Inc.	Modulation of androgen receptor expression
EP2911666B1 (en)	2012-10-26	2022-08-24	Memorial Sloan-Kettering Cancer Center	Modulators of resistant androgen receptor
JOP20200097A1 (ar) *	2013-01-15	2017-06-16	Aragon Pharmaceuticals Inc	معدل مستقبل أندروجين واستخداماته
AU2014273618B2 (en) *	2013-05-29	2016-10-13	Hinova Pharmaceuticals Inc.	Imidazole diketone compound and use thereof
WO2015018356A1 (zh) *	2013-08-08	2015-02-12	上海医药集团股份有限公司	二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用
WO2015042170A1 (en)	2013-09-17	2015-03-26	Wayne State University	Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds
BR112016005000A8 (pt) *	2013-09-19	2018-01-23	Glaxosmithkline Llc	combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, composto
US20160257657A1 (en)	2013-09-20	2016-09-08	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
US10882834B2 (en)	2013-09-20	2021-01-05	University of Pittsburgh—of the Commonwealth System of Higher Education	Compounds for treating prostate cancer
CN103601671B (zh) *	2013-10-22	2016-08-17	上海泰坦科技股份有限公司	碘代三氟甲基吡啶的制备方法
ES2725881T3 (es) *	2013-12-31	2019-09-30	Ipsen Pharma Sas	Nuevos derivados de imidazolidin-2,4-diona
KR20160115999A (ko)	2014-02-14	2016-10-06	더 유니버시티 오브 브리티쉬 콜롬비아	치료제로서의 인간 안드로겐 수용체 dna-결합 도메인(dbd) 화합물 및 그의 사용 방법
CN104003939B (zh) *	2014-06-06	2017-07-07	山东大学	二芳基取代乙内酰硫脲类化合物及其制备方法与应用
WO2015196144A2 (en)	2014-06-20	2015-12-23	England Pamela M	Androgen receptor antagonists
BR112017011788A2 (pt)	2014-12-05	2017-12-26	Aragon Pharmaceuticals Inc	composições anticâncer
CA2969675C (en)	2014-12-05	2023-06-06	Aragon Pharmaceuticals, Inc.	Anticancer compositions
CR20170217A (es) *	2014-12-05	2017-08-30	Aragon Pharmaceuticals Inc	Composiciones anticancerígenas
CA2970469A1 (en)	2014-12-12	2016-06-16	Amy Christian Peterson	Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
SG10201907094QA (en) *	2014-12-19	2019-09-27	Aragon Pharmaceuticals Inc	Processes for the preparation of a diarylthiohydantoin compound
PL3233803T3 (pl) *	2014-12-19	2019-07-31	Aragon Pharmaceuticals, Inc.	Sposób wytwarzania związku diarylotiohydantoiny
CN105732575A (zh) *	2015-02-06	2016-07-06	苏州晶云药物科技有限公司	一种治疗前列腺癌的新型抗雄激素类药物的新晶型及其制备方法
WO2016141458A1 (en)	2015-03-12	2016-09-15	British Columbia Cancer Agency Branch	Bisphenol ether derivatives and methods for using the same
ES2899906T3 (es)	2015-07-06	2022-03-15	Alkermes Inc	Inhibidores bicíclicos de histona desacetilasa
EP3319968A1 (en)	2015-07-06	2018-05-16	Rodin Therapeutics, Inc.	Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
TWI726969B (zh)	2016-01-11	2021-05-11	比利時商健生藥品公司	用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US10980806B2 (en)	2016-03-24	2021-04-20	University of Pittsburgh—of the Commonwealth System of Higher Education	Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
US20170298033A1 (en)	2016-04-15	2017-10-19	The University Of British Columbia	Bisphenol derivatives and their use as androgen receptor activity modulators
EP3500310A1 (en) *	2016-08-20	2019-06-26	FTF Pharma Private Limited	Pharmaceutical composition comprising an androgen receptor inhibitor
CN107954936B (zh) *	2016-10-17	2021-03-19	海创药业股份有限公司	一种制备氘代咪唑二酮类化合物的方法
CN108069869B (zh) *	2016-11-09	2022-03-01	上海医药工业研究院	一种Apalutamide的制备方法及其中间体
ES2952770T3 (es)	2016-12-13	2023-11-06	Watson Lab Inc	Formas de estado sólido de apalutamida
ES2875562T3 (es)	2017-01-11	2021-11-10	Alkermes Inc	Inhibidores bicíclicos de histona desacetilasa
TW201831461A (zh) *	2017-01-18	2018-09-01	台灣神隆股份有限公司	製備阿帕魯醯胺的方法
CN111032644B (zh) *	2017-08-07	2021-08-10	正大天晴药业集团股份有限公司	用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物
US11225475B2 (en)	2017-08-07	2022-01-18	Alkermes, Inc.	Substituted pyridines as inhibitors of histone deacetylase
NZ763299A (en)	2017-09-14	2025-09-26	Daiichi Sankyo Co Ltd	Compound having cyclic structure
EP4438126A3 (en)	2017-10-16	2025-01-01	Aragon Pharmaceuticals, Inc.	Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN108047200A (zh) *	2017-12-05	2018-05-18	上海丰瑞医药科技有限公司	一种二芳基乙内酰硫脲类化合物的制备方法及其中间体
CN108003093A (zh) *	2017-12-07	2018-05-08	山东汇盟生物科技有限公司	2-羟基-3-三氟甲基吡啶的制备方法
CN107987055A (zh) *	2017-12-19	2018-05-04	刘秀云	硫代咪唑二酮类雄激素受体拮抗剂及其用途
CN109988077A (zh) *	2017-12-29	2019-07-09	上海法默生物科技有限公司	一种阿帕鲁胺的合成方法及中间体
WO2019135254A1 (en)	2018-01-02	2019-07-11	Mylan Laboratories Limited	Apalutamide polymorphs and their preparation thereof
US10513504B2 (en)	2018-03-08	2019-12-24	Apotex Inc.	Processes for the preparation of apalutamide and intermediates thereof
US10934269B2 (en) *	2018-03-28	2021-03-02	Cadila Healthcare Limited	Process for preparation of apalutamide
US10807965B2 (en) *	2018-03-28	2020-10-20	Cadila Healthcare Limited	Process for preparation of apalutamide
CN108314646B (zh) *	2018-04-11	2021-03-19	武汉慧敏科技中心	一种高分散双金属纳米材料制备泌尿生殖系统用药物中间体的方法
CN108311155B (zh) *	2018-05-14	2020-11-06	上海奥萝拉医药科技有限公司	一种催化制备治疗前列腺癌症药物阿帕鲁胺中间体的方法
US11485713B2 (en)	2018-05-25	2022-11-01	Essa Pharma, Inc.	Androgen receptor modulators and methods for their use
WO2019242439A1 (zh)	2018-06-20	2019-12-26	苏州科睿思制药有限公司	Arn-509的晶型及其制备方法和用途
CN108976171B (zh)	2018-08-27	2020-06-16	长沙泽达医药科技有限公司	化合物、组合物及其在药物制备中的用途
WO2020049598A2 (en)	2018-09-08	2020-03-12	Cipla Limited	Apalutamide polymorphs
WO2020095183A1 (en)	2018-11-05	2020-05-14	Pfizer Inc.	Combination for treating cancer
AU2019387367A1 (en)	2018-11-30	2021-06-10	Nuvation Bio Inc.	Diarylhydantoin compounds and methods of use thereof
WO2020157699A1 (en)	2019-01-30	2020-08-06	Aragon Pharmaceuticals, Inc.	Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
BR112021015122A2 (pt)	2019-02-01	2021-09-28	Chia Tai Tianqing Pharmaceutical Group Co., Ltd	Cristal de composto de diariltio-hidantoína
IT201900003839A1 (it)	2019-03-15	2020-09-15	Olon Spa	Sintesi di apalutamide amorfa stabile
AU2020248105A1 (en) *	2019-03-28	2021-11-11	Essa Pharma, Inc.	Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
US12109179B2 (en)	2019-03-28	2024-10-08	Essa Pharma Inc.	Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
IT201900010593A1 (it)	2019-07-01	2021-01-01	Dipharma Francis Srl	Forma cristallina di un inibitore di recettori degli androgeni
EP4009969A1 (en)	2019-08-08	2022-06-15	Laekna Limited	Method of treating cancer
EP4017848A1 (en) *	2019-08-22	2022-06-29	Dr. Reddy's Laboratories Ltd.	Process for the preparation of apalutamide
IT201900015974A1 (it)	2019-09-10	2021-03-10	Olon Spa	Apalutamide cristallina stabile in forma pura e processo per la sua preparazione
PE20221167A1 (es) *	2019-11-15	2022-07-25	Kandy Therapeutics Ltd	Nuevo proceso quimico para la elaboracion de 6-cloro-4-(4-fluoro-2-metilfenil)piridin-3-amina, un intermediario clave de nt-814
CN115916170A (zh)	2020-04-17	2023-04-04	埃萨制药股份有限公司	固体形式的n-末端结构域雄激素受体抑制剂及其用途
US20240000783A1 (en)	2020-08-13	2024-01-04	Pfizer Inc.	Combination therapy
WO2022049265A1 (en)	2020-09-04	2022-03-10	Synthon B.V.	Improved process for preparation of apalutamide
CN114621184B (zh) *	2020-12-10	2024-04-26	奥锐特药业股份有限公司	一种阿帕他胺的制备方法
BR112023018906A2 (pt)	2021-03-24	2023-10-10	Astellas Pharma Inc	Combinação de talazoparib e um antiandrógeno para o tratamento de câncer de próstata metastático sensível à castração com mutação no gene ddr
TWI883565B (zh)	2022-10-02	2025-05-11	美商輝瑞大藥廠	用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
WO2024088395A1 (zh) *	2022-10-28	2024-05-02	南京明德新药研发有限公司	桥环类化合物及其在药学上的应用
JP2025537273A (ja) *	2022-11-09	2025-11-14	ブリストル－マイヤーズスクイブカンパニー	置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物との組み合わせ療法
WO2024121163A1 (en)	2022-12-06	2024-06-13	Cancer Research Technology Limited	Combination of 10d1f and an androgen inhibitor for treatment and prevention of cancers
TW202425976A (zh)	2022-12-17	2024-07-01	美商輝瑞大藥廠	用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
WO2025174375A1 (en) *	2024-02-15	2025-08-21	Aragon Pharmaceuticals, Inc.	Anticancer compositions

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE550650A (pl)	1955-08-30
US3823240A (en)	1970-10-06	1974-07-09	Rhone Poulenc Sa	Fungicidal hydantoin derivatives
GB1472467A (en)	1974-04-19	1977-05-04	Wyeth John & Brother Ltd	Thiohydantoins
FR2329276A1 (fr)	1975-10-29	1977-05-27	Roussel Uclaf	Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
DE2614831A1 (de)	1976-04-06	1977-10-20	Bayer Ag	1,3,4-thiadiazolylderivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
MC1220A1 (fr)	1977-10-28	1979-07-20	Hoffmann La Roche	Nouveaux derives d'imidazolidine
CA1138334A (en)	1977-10-28	1982-12-28	Karl Bernauer	Pharmaceutical preparations containing certain urea derivatives
DK543178A (da)	1977-12-01	1979-06-02	Wellcome Found	Thiodydantoinderivater
EP0004723A1 (en)	1978-03-30	1979-10-17	Beecham Group Plc	Deoxyhydantoins, processes for their preparation and pharmaceutical compositions containing them
FR2449448B1 (fr)	1979-02-20	1983-05-27	Inst Nat Radio Elements	Composition pharmaceutique comprenant un derive de phenylhydantoine, derives mis en oeuvre et leur preparation
FI801184A7 (fi)	1979-04-24	1981-01-01	F Hoffmann La Roche & Co	Menetelmä imidatsolidiini-johdannaisten valmistamiseksi.
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
EP0065404A3 (en) *	1981-05-08	1984-06-06	Ace Coin Equipment Limited	Video gaming or amusement machine
JPS57197268A (en)	1981-05-29	1982-12-03	Sumitomo Chem Co Ltd	Substituted phenylhydantoin derivative, its preparation, and herbicide containing the same as active ingredient
EP0091596B1 (de)	1982-04-08	1991-09-11	Shell Internationale Researchmaatschappij B.V.	Neue Hydantoine, ihre Herstellung und Verwendung
US4473393A (en)	1982-08-06	1984-09-25	Buffalo Color Corporation	Pesticidal thiohydantoin compositions
US4559157A (en)	1983-04-21	1985-12-17	Creative Products Resource Associates, Ltd.	Cosmetic applicator useful for skin moisturizing
JPS59210083A (ja) *	1983-05-13	1984-11-28	Otsuka Chem Co Ltd	１，３，４−チアジアゾ−ル−５−オン誘導体、その製造法及び該誘導体を有効成分とする除草剤
LU84979A1 (fr)	1983-08-30	1985-04-24	Oreal	Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
JPS6092285A (ja) *	1983-10-26	1985-05-23	Shionogi & Co Ltd	イソオキサゾ−ル系環状尿素類
JPS60239737A (ja) *	1984-05-14	1985-11-28	Konishiroku Photo Ind Co Ltd	ハロゲン化銀写真感光材料
DE3604042A1 (de)	1986-02-08	1987-08-13	Hoechst Ag	Imidazolidin(thi)on-derivate, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz
US5071773A (en)	1986-10-24	1991-12-10	The Salk Institute For Biological Studies	Hormone receptor-related bioassays
US4820508A (en)	1987-06-23	1989-04-11	Neutrogena Corporation	Skin protective composition
JPS649978A (en) *	1987-07-02	1989-01-13	Shionogi & Co	Perfluoroalkylisoxazole derivative
US4859228A (en)	1987-07-16	1989-08-22	Ici Americas Inc	Novel 5-aminomethylene-2,4-imidazolidinediones and 5-aminomethylene-2-thionoimidazolidine-4-ones
US5010182A (en)	1987-07-28	1991-04-23	Chiron Corporation	DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
FR2619381B1 (fr)	1987-08-13	1989-12-08	Roussel Uclaf	Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
CA1331757C (en)	1988-02-29	1994-08-30	Janssen Pharmaceutica Naamloze Vennootschap	5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
US5614620A (en)	1988-03-30	1997-03-25	Arch Development Corporation	DNA binding proteins including androgen receptor
US4992478A (en)	1988-04-04	1991-02-12	Warner-Lambert Company	Antiinflammatory skin moisturizing composition and method of preparing same
US6307030B1 (en)	1988-04-15	2001-10-23	The University Of North Carolina At Chapel Hill	Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions
JPH0219363A (ja)	1988-07-06	1990-01-23	Fujisawa Pharmaceut Co Ltd	イミダゾリジン誘導体
AU4005289A (en)	1988-08-25	1990-03-01	Smithkline Beecham Corporation	Recombinant saccharomyces
US4938949A (en)	1988-09-12	1990-07-03	University Of New York	Treatment of damaged bone marrow and dosage units therefor
DE3835168A1 (de)	1988-10-15	1990-04-19	Bayer Ag	N-aryl-stickstoffheterocyclen, mehrere verfahren zu ihrer herstellung und ihre verwendung als herbizide
FR2646437B1 (fr)	1989-04-28	1991-08-30	Transgene Sa	Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
FR2656302B1 (fr)	1989-12-22	1992-05-07	Roussel Uclaf	Nouveau procede de preparation de l'anandron et derives de l'anandron.
FR2693461B1 (fr)	1992-07-08	1994-09-02	Roussel Uclaf	Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en)	1991-01-09	1995-05-02	Roussel Uclaf	Phenylimidazolidines having antiandrogenic activity
USRE35956E (en)	1991-01-09	1998-11-10	Roussel Uclaf	Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr)	1991-01-09	1993-03-26	Roussel Uclaf	Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
JP2845384B2 (ja)	1991-11-14	1999-01-13	キヤノン株式会社	画像処理装置
US5346913A (en)	1992-05-26	1994-09-13	Rohm And Haas Company	N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents
FR2694290B1 (fr)	1992-07-08	1994-09-02	Roussel Uclaf	Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en)	1994-01-05	2003-02-21	Hoechst Marion Roussel Inc	New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2715402B1 (fr)	1994-01-05	1996-10-04	Roussel Uclaf	Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
WO1995019770A1 (en)	1994-01-21	1995-07-27	Sepracor, Inc.	Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
JPH089997A (ja)	1994-06-28	1996-01-16	Shimadzu Corp	核酸合成法およびそれに用いる試薬キット
DE69519921T2 (de)	1994-07-29	2001-06-13	Suntory Limited, Osaka	Imidazolidin-derivate und ihre verwendung
FR2725206B1 (fr)	1994-09-29	1996-12-06	Roussel Uclaf	Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en)	1995-06-16	1997-08-12	Biophysica Inc.	Androgenic directed compositions
DE19540027A1 (de) *	1995-10-27	1997-04-30	Gruenenthal Gmbh	Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
FR2741346B1 (fr)	1995-11-16	1997-12-19	Roussel Uclaf	Nouveau procede de preparation de derives phenylimidazolidine
FR2741342B1 (fr)	1995-11-22	1998-02-06	Roussel Uclaf	Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
TW418195B (en) *	1995-11-28	2001-01-11	American Home Prod	2-thioxo-imidazolidin-4-one derivatives
JP2000514401A (ja)	1995-11-28	2000-10-31	アメリカン・ホーム・プロダクツ・コーポレイション	２―（置換スルファニル）―３，５―ジヒドロ―イミダゾール―４―オン誘導体
US5554607A (en) *	1995-11-28	1996-09-10	American Home Products Corporation	Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of atherosclerosis
FR2742749B1 (fr)	1995-12-22	1998-02-06	Roussel Uclaf	Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques
US6489163B1 (en)	1996-05-08	2002-12-03	Board Of Regents, The University Of Texas System	Ribozyme mediated inactivation of the androgen receptor
JP3697320B2 (ja)	1996-06-20	2005-09-21	株式会社日立製作所	光ファイバセンサ
US5726061A (en)	1996-10-08	1998-03-10	Smithkline Beechum Corporation	Method of diagnosing and monitoring colorectal cancer
US7053263B2 (en)	1996-10-15	2006-05-30	The Regents Of The University Of California	Mouse models of human prostate cancer progression
US6506607B1 (en)	1997-12-24	2003-01-14	Millennium Pharmaceuticals, Inc.	Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer
EP1087770A4 (en)	1998-06-15	2001-11-14	Merck & Co Inc	PRENYL PROTEIN TRANSFERASE INHIBITORS
DE59905623D1 (de)	1998-09-22	2003-06-26	Degussa	Verfahren zur Herstellung von Imidazolidin-2,4-dionen
KR100660309B1 (ko)	1998-09-22	2006-12-22	아스텔라스세이야쿠 가부시키가이샤	시아노페닐 유도체
WO2000026195A1 (en) *	1998-10-30	2000-05-11	G.D. Searle & Co.	Novel amino acid heterocyclic amide derivatives useful as nitric oxide synthase inhibitors
US6472415B1 (en)	1998-12-18	2002-10-29	Biophysica, Inc.	Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
AU2847200A (en)	1999-01-27	2000-08-18	G.D. Searle & Co.	Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors
WO2001007048A1 (en) *	1999-07-21	2001-02-01	Boehringer Ingelheim Pharmaceuticals, Inc.	Small molecules useful in the treatment of inflammatory disease
US6479063B2 (en)	1999-12-27	2002-11-12	Kenneth Weisman	Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis
EP1284973B1 (en)	2000-05-31	2007-06-27	Tanabe Seiyaku Co., Ltd.	Inhibitors of alpha l beta 2 mediated cell adhesion
US6482829B2 (en) *	2000-06-08	2002-11-19	Hoffmann-La Roche Inc.	Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
WO2002053155A1 (en)	2000-12-30	2002-07-11	Geron Corporation	Telomerase inhibitor
FR2823209B1 (fr)	2001-04-04	2003-12-12	Fournier Lab Sa	Nouvelles thiohydantoines et leur utilisation en therapeutique
AR036663A1 (es)	2001-10-01	2004-09-22	Bristol Myers Squibb Co	Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios, las composiciones farmaceuticas que las contienen y los intermediarios para preparar dichos compuestos
WO2003032994A2 (de) *	2001-10-17	2003-04-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
US6861432B2 (en)	2001-11-23	2005-03-01	Schering Aktiengesellschaft	Piperazine derivatives that destabilize androgen receptors
GB0200283D0 (en)	2002-01-08	2002-02-20	Smithkline Beecham Plc	Compounds
DE10218963A1 (de)	2002-04-27	2003-11-20	Aventis Pharma Gmbh	Zubereitungen zur topischen Applikation von antiandrogen wirksamen Substanzen
TW200407324A (en) *	2002-05-17	2004-05-16	Bristol Myers Squibb Co	Bicyclic modulators of androgen receptor function
JP2006512924A (ja)	2002-08-15	2006-04-20	ジェンザイム・コーポレーション	脳内皮細胞発現パターン
AU2002951247A0 (en) *	2002-09-06	2002-09-19	Alchemia Limited	Compounds that interact with kinases
FR2845384B1 (fr)	2002-10-04	2004-12-31	Fournier Lab Sa	Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
FR2845385B1 (fr)	2002-10-04	2004-12-31	Fournier Lab Sa	Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
AU2003284005B2 (en) *	2002-10-03	2009-12-17	Forest Laboratories Holdings Limited	Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
AU2003279442A1 (en)	2002-10-04	2004-04-23	Laboratoires Fournier S.A.	2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
UA79504C2 (en)	2002-11-07	2007-06-25	Organon Nv	Indols for treating diseases associated with androgen receptors
FR2850652B1 (fr)	2003-01-31	2008-05-30	Aventis Pharma Sa	Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2004111012A1 (ja)	2003-06-12	2004-12-23	Chugai Seiyaku Kabushiki Kaisha	イミダゾリジン誘導体
AU2004247319A1 (en) *	2003-06-12	2004-12-23	Novo Nordisk A/S	Pyridinyl carbamates as hormone-sensitive lipase inhibitors
PE20050444A1 (es) *	2003-10-31	2005-08-09	Takeda Pharmaceutical	Compuestos de piridina como inhibidores de la peptidasa
US7256208B2 (en)	2003-11-13	2007-08-14	Bristol-Myers Squibb Company	Monocyclic N-Aryl hydantoin modulators of androgen receptor function
AU2004298604B2 (en)	2003-12-15	2010-09-23	The Regents Of The University Of California	Molecular signature of the PTEN tumor suppressor
DE602004031881D1 (de)	2003-12-19	2011-04-28	Univ California	Verfahren und materialien zur beurteilung von prostatakrebstherapien
WO2005099693A2 (en)	2004-02-24	2005-10-27	The Regents Of The University Of California	Methods and materials for assessing prostate cancer therapies and compounds
US8940896B2 (en) *	2004-03-15	2015-01-27	Ptc Therapeutics, Inc.	Tetra-cyclic carboline derivatives useful in the inhibition of angiogenesis
SI1576967T1 (sl) *	2004-03-18	2008-02-29	Pasteur Institut	Rekombinantni protein, ki nosi epitope humanega papilomavirusa, vstavljene v adenilat ciklazni protein ali njegov fragment, in njegove terapevtske uporabe
EP1621536A1 (en)	2004-07-27	2006-02-01	Aventis Pharma S.A.	Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621539A1 (en) *	2004-07-27	2006-02-01	Aventis Pharma S.A.	Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
ATE503746T1 (de)	2004-08-03	2011-04-15	Chugai Pharmaceutical Co Ltd	Neue imidazolidinderivate
CN101676270A (zh)	2004-09-09	2010-03-24	中外制药株式会社	新型四氢咪唑衍生物及其用途
RS52274B2 (sr) *	2005-05-13	2018-05-31	Univ California	Jedinjenje diarilhidantoina
US7709517B2 (en)	2005-05-13	2010-05-04	The Regents Of The University Of California	Diarylhydantoin compounds
GB0521373D0 (en) *	2005-10-20	2005-11-30	Kudos Pharm Ltd	Pthalazinone derivatives
CN101032483B (zh) *	2006-03-09	2011-05-04	陈德桂	调节雄激素受体活性的乙内酰脲衍生物及其应用
PL3412290T3 (pl) *	2006-03-27	2021-09-06	The Regents Of The University Of California	Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym
CA2648139A1 (en)	2006-03-29	2007-11-08	The Regents Of The University Of California	Diaryl thiohydantoin compounds and their use in the treatment of hyperproliferative disorders
WO2008119015A2 (en)	2007-03-27	2008-10-02	Sloan-Kettering Institute For Cancer Research	Synthesis of thiohydantoins

2007
- 2007-03-27 PL PL18181743T patent/PL3412290T3/pl unknown
- 2007-03-27 EP EP13178051.2A patent/EP2656842B1/en active Active
- 2007-03-27 DK DK13178051.2T patent/DK2656842T3/en active
- 2007-03-27 PT PT111639480T patent/PT2368550E/pt unknown
- 2007-03-27 DK DK13178047.0T patent/DK2656841T3/en active
- 2007-03-27 EP EP16173574.1A patent/EP3100727B1/en active Active
- 2007-03-27 SI SI200732176T patent/SI3412290T1/sl unknown
- 2007-03-27 NZ NZ572335A patent/NZ572335A/en unknown
- 2007-03-27 PL PL16173574T patent/PL3100727T3/pl unknown
- 2007-03-27 SI SI200731829A patent/SI2656841T1/sl unknown
- 2007-03-27 LT LTEP13178047.0T patent/LT2656841T/lt unknown
- 2007-03-27 LT LTEP13178051.2T patent/LT2656842T/lt unknown
- 2007-03-27 HU HUE16173574A patent/HUE042037T2/hu unknown
- 2007-03-27 PT PT181817438T patent/PT3412290T/pt unknown
- 2007-03-27 ES ES18181743T patent/ES2863798T3/es active Active
- 2007-03-27 CN CN2007800196547A patent/CN101454002B/zh active Active
- 2007-03-27 JP JP2009502925A patent/JP5133975B2/ja active Active
- 2007-03-27 PT PT16173574T patent/PT3100727T/pt unknown
- 2007-03-27 EP EP21153358.3A patent/EP3835294A1/en not_active Withdrawn
- 2007-03-27 HU HUE18181743A patent/HUE053877T2/hu unknown
- 2007-03-27 EP EP24159183.3A patent/EP4385574A3/en not_active Withdrawn
- 2007-03-27 EP EP13178047.0A patent/EP2656841B1/en active Active
- 2007-03-27 LT LTEP16173574.1T patent/LT3100727T/lt unknown
- 2007-03-27 HU HUE13178051A patent/HUE032085T2/en unknown
- 2007-03-27 BR BRPI0709771-9A patent/BRPI0709771B1/pt active IP Right Grant
- 2007-03-27 EP EP18181743.8A patent/EP3412290B1/en active Active
- 2007-03-27 ES ES11163948T patent/ES2428291T3/es active Active
- 2007-03-27 HU HUE13178047A patent/HUE031079T2/en unknown
- 2007-03-27 PL PL13178051T patent/PL2656842T3/pl unknown
- 2007-03-27 ES ES07754060T patent/ES2564388T7/es active Active
- 2007-03-27 SI SI200731340T patent/SI2368550T1/sl unknown
- 2007-03-27 DK DK16173574.1T patent/DK3100727T3/en active
- 2007-03-27 SI SI200732058T patent/SI3100727T1/sl unknown
- 2007-03-27 SI SI200731759A patent/SI2004181T1/sl unknown
- 2007-03-27 DK DK18181743.8T patent/DK3412290T3/da active
- 2007-03-27 FI FIEP07754060.7T patent/FI2004181T6/fi active
- 2007-03-27 PL PL07754060.7T patent/PL2004181T6/pl unknown
- 2007-03-27 HU HUE07754060A patent/HUE027894T2/en unknown
- 2007-03-27 DK DK11163948.0T patent/DK2368550T3/da active
- 2007-03-27 EP EP11163948.0A patent/EP2368550B1/en active Active
- 2007-03-27 EP EP07754060.7A patent/EP2004181B3/en active Active
- 2007-03-27 PT PT131780470T patent/PT2656841T/pt unknown
- 2007-03-27 ES ES13178047.0T patent/ES2593379T3/es active Active
- 2007-03-27 DK DK07754060.7T patent/DK2004181T6/da active
- 2007-03-27 WO PCT/US2007/007485 patent/WO2007126765A2/en not_active Ceased
- 2007-03-27 PL PL11163948T patent/PL2368550T3/pl unknown
- 2007-03-27 LT LTEP18181743.8T patent/LT3412290T/lt unknown
- 2007-03-27 US US12/294,881 patent/US8445507B2/en active Active
- 2007-03-27 ES ES13178051.2T patent/ES2588606T3/es active Active
- 2007-03-27 PT PT131780512T patent/PT2656842T/pt unknown
- 2007-03-27 ES ES16173574.1T patent/ES2689292T3/es active Active
- 2007-03-27 SI SI200731821A patent/SI2656842T1/sl unknown
- 2007-03-27 PL PL13178047T patent/PL2656841T3/pl unknown
- 2007-03-27 AU AU2007243651A patent/AU2007243651C1/en active Active
2012
- 2012-02-10 JP JP2012027792A patent/JP6057518B2/ja active Active
- 2012-09-13 US US13/615,085 patent/US8802689B2/en active Active
2013
- 2013-11-18 CY CY20131101020T patent/CY1114623T1/el unknown
2014
- 2014-04-15 JP JP2014083382A patent/JP2014133755A/ja not_active Withdrawn
- 2014-06-27 US US14/318,234 patent/US9388159B2/en active Active
2015
- 2015-10-19 JP JP2015205260A patent/JP6027662B2/ja active Active
- 2015-10-19 JP JP2015205261A patent/JP2016014069A/ja not_active Withdrawn
2016
- 2016-05-23 CY CY20161100444T patent/CY1117540T1/el unknown
- 2016-06-13 US US15/181,030 patent/US9987261B2/en active Active
- 2016-09-02 CY CY20161100864T patent/CY1117958T1/el unknown
- 2016-09-21 CY CY20161100936T patent/CY1118026T1/el unknown
2017
- 2017-03-16 JP JP2017050929A patent/JP6422519B2/ja active Active
2018
- 2018-02-01 JP JP2018016157A patent/JP6701237B2/ja active Active
- 2018-05-02 US US15/969,147 patent/US10857139B2/en active Active
- 2018-10-30 CY CY181101115T patent/CY1120828T1/el unknown
2019
- 2019-03-11 JP JP2019043597A patent/JP2019081815A/ja not_active Withdrawn
- 2019-05-22 HU HUS1900030C patent/HUS1900030I1/hu unknown
- 2019-05-24 CY CY2019028C patent/CY2019028I1/el unknown
- 2019-06-04 LU LU00123C patent/LUC00123I2/fr unknown
- 2019-06-05 NL NL300993C patent/NL300993I2/nl unknown
- 2019-06-13 LT LTPA2019512C patent/LTC2368550I2/lt unknown
2020
- 2020-09-04 JP JP2020148926A patent/JP7257692B2/ja active Active
- 2020-11-09 US US17/093,047 patent/US11771687B2/en active Active
2021
- 2021-05-14 CY CY20211100418T patent/CY1124147T1/el unknown
2022
- 2022-11-08 JP JP2022178761A patent/JP2023001259A/ja not_active Withdrawn
2023
- 2023-10-02 US US18/375,628 patent/US20240293383A1/en not_active Abandoned

Also Published As

Publication number	Publication date
SI2656842T1 (sl)	2016-10-28
HK1190928A1 (en)	2014-07-18
EP2656841A1 (en)	2013-10-30
EP2656842A3 (en)	2014-04-02
DK2004181T3 (en)	2016-04-25
DK2004181T6 (da)	2023-08-21
EP2004181A2 (en)	2008-12-24
HUE032085T2 (en)	2017-09-28
EP3100727B1 (en)	2018-08-22
EP3412290B1 (en)	2021-03-03
HUE031079T2 (en)	2017-06-28
US20180318276A1 (en)	2018-11-08
PT2368550E (pt)	2013-12-03
ES2588606T3 (es)	2016-11-03
JP2018065879A (ja)	2018-04-26
LUC00123I1 (pl)	2019-06-06
US20130072511A1 (en)	2013-03-21
CY2019028I2 (el)	2019-11-27
DK2656842T3 (en)	2016-11-07
CY1114623T1 (el)	2016-10-05
SI3100727T1 (sl)	2018-11-30
US11771687B2 (en)	2023-10-03
BRPI0709771B1 (pt)	2022-01-25
JP2009531439A (ja)	2009-09-03
JP2014133755A (ja)	2014-07-24
EP2368550A1 (en)	2011-09-28
PT3412290T (pt)	2021-04-19
ES2863798T3 (es)	2021-10-11
NL300993I2 (nl)	2019-07-11
HK1163495A1 (en)	2012-09-14
US9987261B2 (en)	2018-06-05
EP2656842A2 (en)	2013-10-30
US20210121450A1 (en)	2021-04-29
JP6701237B2 (ja)	2020-05-27
JP2012092149A (ja)	2012-05-17
US9388159B2 (en)	2016-07-12
SI3412290T1 (sl)	2021-09-30
US20110003839A1 (en)	2011-01-06
PL2004181T6 (pl)	2023-09-04
CN101454002A (zh)	2009-06-10
LT3100727T (lt)	2018-12-10
PL3412290T3 (pl)	2021-09-06
EP3100727A1 (en)	2016-12-07
WO2007126765A3 (en)	2008-11-06
PL2656842T3 (pl)	2017-01-31
PT3100727T (pt)	2018-11-09
LTPA2019512I1 (lt)	2019-07-25
JP2019081815A (ja)	2019-05-30
HUE042037T2 (hu)	2019-06-28
JP2016014069A (ja)	2016-01-28
EP2004181B1 (en)	2016-02-24
PL3100727T3 (pl)	2019-01-31
JP7257692B2 (ja)	2023-04-14
LTC2368550I2 (lt)	2020-01-10
JP6422519B2 (ja)	2018-11-14
CY2019028I1 (el)	2019-11-27
PT2656841T (pt)	2016-09-28
EP2656842B1 (en)	2016-08-10
BRPI0709771A2 (pt)	2011-07-26
US10857139B2 (en)	2020-12-08
EP4385574A2 (en)	2024-06-19
JP2017105845A (ja)	2017-06-15
LT2656841T (lt)	2016-09-26
HUS1900030I1 (hu)	2020-04-28
EP2656841B1 (en)	2016-08-10
ES2689292T3 (es)	2018-11-13
US8445507B2 (en)	2013-05-21
ES2564388T7 (es)	2023-12-21
PL2656841T3 (pl)	2017-01-31
US20170014399A1 (en)	2017-01-19
PL2368550T3 (pl)	2014-01-31
ES2564388T3 (es)	2016-03-22
EP3412290A1 (en)	2018-12-12
SI2656841T1 (sl)	2016-11-30
NZ572335A (en)	2011-09-30
AU2007243651A1 (en)	2007-11-08
SI2004181T1 (sl)	2016-07-29
CY1117958T1 (el)	2017-05-17
AU2007243651B2 (en)	2012-08-30
DK3412290T3 (da)	2021-04-19
JP6027662B2 (ja)	2016-11-16
SI2368550T1 (sl)	2013-11-29
LT2656842T (lt)	2016-09-26
US8802689B2 (en)	2014-08-12
CY1120828T1 (el)	2019-12-11
FI2004181T6 (fi)	2023-09-01
US20240293383A1 (en)	2024-09-05
JP2020193234A (ja)	2020-12-03
JP6057518B2 (ja)	2017-01-11
HK1126421A1 (zh)	2009-09-04
EP2368550B1 (en)	2013-09-04
ES2593379T3 (es)	2016-12-09
CY1124147T1 (el)	2022-05-27
CN101454002B (zh)	2011-06-08
DK2656841T3 (en)	2016-12-05
CY1117540T1 (el)	2017-04-26
WO2007126765A2 (en)	2007-11-08
AU2007243651C1 (en)	2013-03-14
DK2368550T3 (da)	2013-09-30
JP5133975B2 (ja)	2013-01-30
HUE053877T2 (hu)	2021-07-28
EP3835294A1 (en)	2021-06-16
LT3412290T (lt)	2021-04-26
HUE027894T2 (en)	2016-11-28
PT2656842T (pt)	2016-10-04
EP2004181A4 (en)	2010-11-10
EP2004181B3 (en)	2023-05-24
JP2016011315A (ja)	2016-01-21
HK1231375A1 (en)	2017-12-22
US20140309262A1 (en)	2014-10-16
JP2023001259A (ja)	2023-01-04
ES2428291T3 (es)	2013-11-06
DK3100727T3 (en)	2018-11-12
LUC00123I2 (pl)	2019-12-27
CY1118026T1 (el)	2017-05-17
EP4385574A3 (en)	2024-10-02

Publication	Publication Date	Title
HUS1900030I1 (hu)	2020-04-28	Androgén receptor modulátorok a prosztatarák és androgén receptorral összefüggõ betegségek kezelésére
IL185491A0 (en)	2008-01-06	Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
IL206563A0 (en)	2010-12-30	Medicament for the treatment of cancer of the pancreas
IL197315A0 (en)	2009-12-24	Treatment of cancer
EP2049151A4 (en)	2010-03-24	METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2144887A4 (en)	2012-10-03	PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
IL226363A0 (en)	2013-06-27	Compounds and methods for treating cancer
IL205339A0 (en)	2010-12-30	Compounds and methods for the treatment of cancer
GB0700281D0 (en)	2007-02-14	Methods and Means for the Treatment of Cancer
GB0600903D0 (en)	2006-02-22	Treatment of cancer
AU2006906276A0 (en)	2006-11-23	Compositions and methods for the treatment of prostate cancer
HK1126130A (en)	2009-08-28	Combination therapy for the treatment of cancer
GB0604114D0 (en)	2006-04-12	Combinations for the treatment of cancer
GB0622581D0 (en)	2006-12-20	Treatment of cancer